Rosenblum Silverman Sutton’s Heron Therapeutics HRTX Stock Holding History

Rosenblum Silverman Sutton’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-65,187	Closed	-$959K	–	65
2020 Q2	$959K	Sell	65,187 -860	-1%	-$14.1K	0.31%	43
2020 Q1	$775K	Sell	66,047 -13,467	-17%	-$253K	0.31%	49
2019 Q4	$1.87M	Sell	79,514 -60,564	-43%	-$1.34M	0.68%	41
2019 Q3	$2.59M	Sell	140,078 -474	-0.3%	-$8.72K	1%	35
2019 Q2	$2.61M	Sell	140,552 -1,585	-1%	-$31.7K	0.99%	34
2019 Q1	$3.47M	Buy	+142,137	New	+$3.72M	1.38%	31

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Rosenblum Silverman Sutton's HRTX Position: Q3 2020 in Review

Rosenblum Silverman Sutton sold out of Heron Therapeutics (HRTX) in Q3 2020, closing a stake of 65,187 shares — an estimated $959K sold.

Rosenblum Silverman Sutton first reported a position in HRTX in Q1 2019 and held it in 6 quarters. The position peaked at $3.47M in Q1 2019. 182 funds tracked by Wall St. Rank hold HRTX as of Q3 2020.

Rosenblum Silverman Sutton reported no remaining Heron Therapeutics position as of Q3 2020 after selling out during the quarter.
Rosenblum Silverman Sutton sold 65,187 Heron Therapeutics shares in Q3 2020, an estimated $959K.
Rosenblum Silverman Sutton first reported a position in Heron Therapeutics in Q1 2019 and held it in 6 quarters.
Rosenblum Silverman Sutton's Heron Therapeutics position peaked at $3.47M in Q1 2019.
182 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2020.

Based on Rosenblum Silverman Sutton's 13F filing for Q3 2020, filed 9 Nov 2020.